Journal article
Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation
Abstract
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce heart failure (HF) in a broad range of populations, but they have not been studied specifically in patients with atrial fibrillation (AF). We aimed to examine the association between SGLT2i eligibility and cardiovascular events in patients with AF to evaluate the potential utility of SGLT2is for AF management.
METHODS: We pooled data from 2 randomized controlled trials (RCTs) …
Authors
Oraii A; Healey JS; Benz AP; Pandey AK; Wong JA; Fonguh S; Wang J; Conen D; Gerstein HC; Connolly SJ
Journal
Canadian Journal of Cardiology, Vol. 38, No. 9, pp. 1434–1441
Publisher
Elsevier
Publication Date
September 2022
DOI
10.1016/j.cjca.2022.05.004
ISSN
0828-282X